Pediatric bladder tissue engineering: Where have we been and where do we go next?

OBJECTIVES

This review aims to (a) provide a concise overview of early clinical trials in bladder tissue engineering and the associated challenges, (b) evaluate significant advancements over the past 15 years in addressing key limitations in angiogenesis, scaffolding, cell sourcing, and immunomodulation, and (c) explore the individual and synergistic contributions of each domain toward the development of a viable engineered solution.

MATERIALS AND

METHODS

Relevant papers for this narrative review were selected through a PubMed search for "bladder tissue engineering" studies published between 01/01/2009 and 12/31/2024, as well as earlier clinical trials that predate this period.

RESULTS

Along with reviewing four major clinical trials, this review highlights nearly 20 distinct studies that showcase progress in the critical domains of angiogenesis, scaffolding, cell sourcing, and immunomodulation.

CONCLUSIONS

Are we close to developing an off-the-shelf bladder substitute? Not yet. Current efforts are focused on addressing two major knowledge gaps: (a) the lack of testing in clinically relevant disease models and (b) the need for a more comprehensive understanding of engineered tissue physiology.